商品情報にスキップ
1 2

Cialis Lifecycle Management: Lilly's BPH Dilemma

通常価格 ¥1,342 JPY
通常価格 セール価格 ¥1,342 JPY
セール 売り切れ
税込み。
書籍サイズ
ページ数

How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new indication, benign prostatic hyperplasia (BPH), soon to be carried out, the team had to make a decision soon. On its face, the market opportunity for a BPH indication, and its synergies with an ED drug, seemed enormous: both ED and BPH were age-related conditions, and data showed that half of men with ED had BPH symptoms. Moreover, the BPH indication would be taken in the same frequency and dosing as the once-a-day version of Cialis. However, market research had revealed significant challenges in introducing the BPH indication under the Cialis name. For example, although ED and BPH often co-existed, men perceived them quite differently. Some physicians also reacted negatively to the BPH indication. Impending competition from low-price ED generics, given that Viagra would soon be going off patent, underscored the importance of the BPH opportunity.

【書誌情報】

ページ数:24ページ

サイズ:A4

商品番号:HBSP-513005

発行日:2012/9/26

登録日:2012/12/21

1 3